NCT01178580

Brief Summary

Community acquired pneumonia (CAP) is still one of the most important causes of morbidity in adults. (1) In severe cases, parapneumonic effusions or empyema may develop. In these patients, a transitional fibrin neomatrix constitutes part of the acute inflammatory response as seen in sepsis. The aim is to study the fibrinolytic activity in patients with CAP alone versus CAP with parapneumonic effusions with and without empyema.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2010

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 8, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 10, 2010

Completed
3 months until next milestone

Study Start

First participant enrolled

November 1, 2010

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2011

Completed
Last Updated

September 7, 2011

Status Verified

September 1, 2011

Enrollment Period

9 months

First QC Date

August 8, 2010

Last Update Submit

September 5, 2011

Conditions

PneumoniaPleural EffusionEmpyema

Keywords

fibrinolytic activityCommunity acquired pneumonia (CAP)Pleural effusion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

all patients that will be admitted with CAP to the pulmonary department in Meir Medical Center and have no exclusion criteria will be included in the study

You may not qualify if:

  • Patients younger than 18 years old
  • Patients with anticoagulant treatment, primary coagulopathy, nephrotic syndrome, surgery, other infection in the month preceding the study, an abnormal liver or renal function test(s), a history of deep vein thrombosis in the last year or patients with acute coronary syndrome.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pulmonary department, Meir Medical Center

Kfar Saba, Israel, 49100, Israel

Location

MeSH Terms

Conditions

PneumoniaPleural EffusionEmpyemaCommunity-Acquired Pneumonia

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsLung DiseasesRespiratory Tract DiseasesPleural DiseasesSuppurationInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsCommunity-Acquired Infections

Study Officials

  • David Shitrit, MD

    Meir Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 8, 2010

First Posted

August 10, 2010

Study Start

November 1, 2010

Primary Completion

August 1, 2011

Study Completion

August 1, 2011

Last Updated

September 7, 2011

Record last verified: 2011-09

Locations

IL(1)